AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain
AstraZeneca wasn’t expected to have data from the Phase 3 trial of its oral SERD until the second half of this year so the positive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
